TransCode Therapeutics will present clinical data from its Phase 1a trial of TTX-MC138, a novel RNA-based cancer therapy targeting metastatic solid tumors, at the ESMO Congress 2026 in Madrid. The drug targets microRNA-10b, linked to cancer metastasis, and is currently advancing in clinical development including a Phase 2a trial. This presentation highlights progress in treating advanced cancers with innovative immuno-oncology approaches, signaling potential future treatment options for metastatic disease. The event runs from October 23-27, 2026, providing a platform for global oncology experts to review these findings.
TransCode Therapeutics' clinical trial update offers context for readers. For those tracking health-sector stocks, 68 of 150 US stocks rose and 54 fell on Pluang. Notable movers include Sanofi SA at USD 40.09 with a -1.28% change, Moderna at USD 215.33 down -1.23%, and Immunovant Inc. up 1.20% at USD 27.05, as of Oct 19, 2026 18:43 WIB.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
